Impact of sodium chloride on the expansion of a liquid-liquid miscibility gap in an API/water system. Case study of Brivaracetam

Add time:07/22/2019    Source:sciencedirect.com

Brivaracetam, or (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butanamide, is an active pharmaceutical ingredient designed for the treatment of epilepsy. During the development of the IV administration mode, a liquid-liquid miscibility gap has been observed with pure water, isotonic and hypertonic solutions (vehicle at 0.9% w/w and 5%w/w NaCl respectively). The study reveals that the NaCl concentration has a direct impact on the extent of the demixing domain; from a sub-micronic demixing in pure water towards a macroscopic miscibility gap in hypertonic aqueous solutions. The thorough exploration of these heterogeneous equilibria led to define experimental parameters for safe IV injections without risk of liquid – liquid miscibility gap at 37 °C.

We also recommend Trading Suppliers and Manufacturers of 4-(2-OXO-PYRROLIDIN-1-YL)-BENZENESULFONYL CHLORIDE (cas 112539-09-0). Pls Click Website Link as below: cas 112539-09-0 suppliers

Prev:Biosynthesis and structural characterization of polyhydroxyalkanoates produced by Pseudomonas aeruginosa ATCC 27853 from long odd-chain fatty acids
Next:A Novel Sialidase Capable of Cleaving 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid (cas 112543-66-5) (KDN))